Unknown

Dataset Information

Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.


ABSTRACT: Traumatic brain injuries represent a leading cause of death and disability in the paediatric and adult populations. Moderate-to-severe injuries are associated with blood-brain barrier dysfunction, the development of cerebral oedema, and neuroinflammation. Antagonists of the tachykinin NK1 receptor have been proposed as potential agents for the post-injury treatment of TBI. We report on the identification of EUC-001 as a potential clinical candidate for development as a novel TBI therapy. EUC-001 is a selective NK1 antagonist with a high affinity for the human NK1 receptor (Ki 5.75 × 10-10 M). It has sufficient aqueous solubility to enable intravenous administration, whilst still retaining good CNS penetration as evidenced by its ability to inhibit the gerbil foot-tapping respons

SUBMITTER: Vink R 

PROVIDER: S-EPMC10970734 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature